Delving into the Latest Updates on J2H Biotech, Inc. with Synapse

Overview

Tags

Neoplasms

Respiratory Diseases

Other Diseases

Small molecule drug

Proteolysis-targeting chimeras (PROTAC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Nervous System Diseases	2
Immune System Diseases	2
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	8
Proteolysis-targeting chimeras (PROTAC)	3
Unknown	1

Top 5 Target	Count

11β-HSD(11-beta-hydroxysteroid dehydrogenase)	1

Abstract11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) is a key enzyme that catalyzes the intracellular conversion of cortisone to physiologically active cortisol. Although 11βHSD1 has been implicated in numerous metabolic syndromes, such as obesity and diabetes, the functional roles of 11βHSD1 during progression of nonalcoholic steatohepatitis (NASH) and consequent fibrosis have not been fully elucidated. We found that pharmacological and genetic inhibition of 11βHSD1 resulted in reprogramming of hepatic stellate cell (HSC) activation via inhibition of p-SMAD3, α-SMA, Snail, and Col1A1 in a fibrotic environment and in multicellular hepatic spheroids (MCHSs). We also determined that 11βHSD1 contributes to the maintenance of NF-κB signaling through modulation of TNF, TLR7, ITGB3, and TWIST, as well as regulating PPARα signaling and extracellular matrix accumulation in activated HSCs during advanced fibrogenesis in MCHSs. Of great interest, the 11βHSD1 inhibitor J2H-1702 significantly attenuated hepatic lipid accumulation and ameliorated liver fibrosis in diet- and toxicity-induced NASH mouse models. Together, our data indicate that J2H-1702 is a promising new clinical candidate for the treatment of NASH.

100 Deals associated with J2H Biotech, Inc.

Login to view more data

100 Translational Medicine associated with J2H Biotech, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

8

Preclinical

Phase 1 Clinical

1

Phase 2 Clinical

Other

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

J2H-1702 ( 11β-HSD )	Nonalcoholic Steatohepatitis More	Phase 2
J2H-1701	Hepatitis C More	Phase 1
J2H-P1905	Idiopathic Pulmonary Fibrosis More	Preclinical
J2H-1802	Psoriasis More	Preclinical
J2H-1908	Solid tumor More	Preclinical